New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review
Despite improvements in the treatment of patients with newly diagnosed multiple myeloma (MM) through the introduction of new drugs and high-dose chemotherapy with autologous hematopoietic stem cell transplantation, relapses are still inevitable in all patients. The use of immunomodulatory agents (th...
Saved in:
| Main Author: | OM Votyakova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2017-10-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2017/10/1_1.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series
by: Tomoki Suichi, et al.
Published: (2025-12-01) -
Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
by: OM Votyakova
Published: (2016-10-01) -
Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy
by: Perrone V, et al.
Published: (2025-07-01) -
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma
by: Luqun Wang, et al.
Published: (2025-05-01) -
Unexpected hope for a multiple myeloma patient
by: Minodora Cezarina Onisâi, et al.
Published: (2020-10-01)